Published on 30/11/2025

KPI Templates for Change Board Review

In the pharmaceutical industry, effective change control is essential to ensure compliance with regulations and maintain product integrity. Change control impact assessments, verification versus re-validation processes, and appropriate risk-based change thresholds serve to protect both patient safety and product quality. In this article, we will provide a detailed step-by-step tutorial on creating KPI templates specifically designed for Change Board Review, focusing on pivotal areas such as evidence packs, bridging studies, and sampling plan updates.

Step 1: Understanding Change Control Impact Assessment

Change control impact assessments are a systematic approach for evaluating the potential effects of a proposed change in a pharmaceutical process or product. This includes changes affecting packaging, raw materials, and equipment, among other factors. By properly assessing the impact, companies can identify any risks associated with the change and make informed decisions that keep regulatory requirements in alignment.

The process begins with a clear definition of the change. This can include adjustments to packaging components, formulation modifications, or alterations in manufacturing techniques. Once the change is defined, the following components are typically included in the impact assessment:

• Scope of the Change: Clearly outline what is being changed and why it is necessary.
• Risk Assessment: Evaluate potential risks associated with the change based on the specific characteristics of the product.
• Regulatory Considerations: Identify any guidelines or regulations affected by the change, referencing key documents such as 21 CFR Part 211.
• Validation Needs: Determine if the change requires validation activities, and delineate between the verification and re-validation processes.

Given the importance of this assessment, integrating it into your KPI template is vital. The template should include fields for summarizing the findings of the impact assessment, categorizing the changes by risk level, and determining their method of evaluation.

Step 2: Differentiating Verification vs Re-Validation

A key part of change control is understanding the distinction between verification and re-validation. Verification typically occurs when the change does not affect critical quality attributes or when the existing process remains stable. In contrast, re-validation is required when a change fundamentally alters the product or system.

To assist in this process, KPI templates must provide clear definitions and criteria for making these determinations. Consider the following:

• Verification: Should include checks for minor changes or adjustments that do not require extensive re-evaluation.
• Re-Validation: Must involve a rigorous and comprehensive validation exercise if there are significant changes noted.

Creating a decision matrix within the KPI template can lend clarity to this distinction, enabling teams to quickly ascertain the need for re-validation versus verification by referencing defined criteria against proposed changes.

Step 3: Risk-Based Change Thresholds

The implementation of risk-based change thresholds is integral to effective change management in the pharmaceutical industry. By establishing threshold levels, organizations can ensure that changes are evaluated according to the potential risks they pose to product quality, safety, or efficacy.

In your KPI template, consider including sections to categorize changes according to predefined thresholds. Here’s how you can lay this out:

• Low Risk: Changes that are less likely to impact product quality or safety; these may include minor modifications to packaging or labeling.
• Moderate Risk: Changes that have potential impacts but can be managed without extensive re-evaluation; examples include alterations to raw materials.
• High Risk: Significant changes requiring comprehensive assessments, including bridging studies or extensive re-validation procedures.

Utilizing a scoring system may also prove beneficial. By assigning numeric values based on severity and likelihood of occurrence, teams can automate logic to determine the needed level of scrutiny for specific changes.

Step 4: Integrating Bridging Studies into the Review Process

Bridging studies are essential when changes in the manufacturing process or raw materials require the establishment of comparability. These studies offer vital evidence to support claims that the changes made do not adversely affect the quality attributes of the product.

When creating KPI templates, ensure to incorporate sections dedicated to documenting bridging study requirements and results. This section should include the following elements:

• Study Objectives: Clearly outline what the bridging study intends to achieve and the parameters being compared.
• Methodology: Detail the design and conduct of the bridging study, including sampling plans and statistical analysis used.
• Results Summary: Key findings should be highlighted to show that the proposed change maintains product quality.
• Regulatory Fit: Reference relevant guidelines, including Annex 15, to ensure consistency with other regulatory requirements.

This comprehensive approach ensures that bridging studies are seamlessly integrated into the change control framework, supporting a well-rounded evaluation process.

Step 5: Establishing Sampling Plan Updates

Sampling plans are critical for quality assurance in confirming that outcomes meet specified limits. It is essential to review and, if necessary, update sampling plans whenever changes occur to ensure they remain adequate for the new circumstances.

When addressing sampling in your KPI templates, include the following components:

• Current Sampling Plan: Provide details of the existing sampling plan prior to the change.
• Impact of Change: Assess how the change might lead to a need to update or modify the sampling plan.
• New Sampling Strategy: Clearly outline how the new plan should look, including sample sizes, frequency of sampling, and any specific methods employed.
• Acceptance Criteria: Define the criteria that must be met under the revised plan.

A thorough examination of sampling plans helps to validate that adjustments made during the change control process align with regulatory expectations while upholding product quality standards.

Step 6: Effectiveness Checks and Periodic Review

To ensure that established control measures remain effective over time, organizations must conduct effectiveness checks and periodic reviews of the implemented changes. Adapting KPI templates to accommodate these factors will provide greater visibility into the change control lifecycle.

Consider incorporating sections within your KPI template for:

• Effectiveness Checks: Provide a framework for evaluating the effectiveness of implemented changes. Detail metrics for measuring success and passing benchmarks.
• Periodic Review: Establish a schedule for regular assessments of the changes, documenting the frequency and outcomes of these reviews.
• Feedback Loop: Create a mechanism whereby findings from effectiveness checks lead to updates in procedures or practices as needed.

This approach fosters a responsive and quality-centric culture, aligning with the best practices encouraged by regulatory bodies such as the PIC/S.

Conclusion

Utilizing KPI templates for Change Board Review within the pharmaceutical industry is an essential part of the change control process. By following the structured steps outlined above—understanding impact assessments, differentiating verification and re-validation, implementing risk-based thresholds, integrating bridging studies, updating sampling plans, and ensuring robust effectiveness checks—pharmaceutical professionals can maintain compliance while fostering a culture of continuous improvement.

The successful application of these templates contributes to the overall mission of ensuring patient safety and product integrity. With the right tools, processes, and understanding, professionals can navigate the complexities of change control effectively, staying ahead of ever-evolving regulatory expectations in the US, UK, and EU.